EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

Pyronaridine as a Bromodomain-Containing Protein 4-N-Terminal Bromodomain (BRD4-BD1) Inhibitor: In Silico Database Mining, Molecular Docking, and Molecular Dynamics Simulation

Mahmoud A A Ibrahim iD, Mahmoud M H Abdelhamid iD, Khlood A A Abdeljawaad iD, Alaa H M Abdelrahman iD, Gamal A H Mekhemer iD, Peter A Sidhom iD, Shaban R M Sayed, Paul W Paré iD, Mohamed-Elamir F Hegazy iD, Tamer Shoeib iD

Molecules · 2023

DOI: 10.3390/molecules28155713 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, 2023. Verfasst von Mahmoud A A Ibrahim und 9 weiteren Autor:innen. Beteiligte Einrichtung: Computational Chemistry Laboratory, Chemistry Department, Faculty of Science, Minia University, Minia 61519, Egypt. Hauptthemen laut MEDLINE: Molecular Dynamics Simulation, Nuclear Proteins. Die Arbeit wurde bisher 10-mal zitiert (Crossref) und nennt 58 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

BRD4 (bromodomain-containing protein 4) is an epigenetic reader that realizes histone proteins and promotes the transcription of genes linked to cancer progression and non-cancer diseases such as acute heart failure and severe inflammation. The highly conserved N-terminal bromodomain (BD1) recognizes acylated lysine residues to organize the expression of genes. As such, BD1 is essential for disrupting BRD4 interactions and is a promising target for cancer treatment. To identify new BD1 inhibitors, a SuperDRUG2 database that contains more than 4600 pharmaceutical compounds was screened using in silico techniques. The efficiency of the AutoDock Vina1.1.2 software to anticipate inhibitor-BRD4-BD1 binding poses was first evaluated based on the co-crystallized R6S ligand in complex with BRD4-BD1. From database screening, the most promising BRD4-BD1 inhibitors were subsequently submitted to molecular dynamics (MD) simulations integrated with an MM-GBSA approach. MM-GBSA computations indicated promising BD1 binding with a benzonaphthyridine derivative, pyronaridine (SD003509), with an energy prediction (ΔGbinding) of −42.7 kcal/mol in comparison with −41.5 kcal/mol for a positive control inhibitor (R6S). Pharmacokinetic properties predicted oral bioavailability for both ligands, while post-dynamic analyses of the BRD4-BD1 binding pocket demonstrated greater stability for pyronaridine. These results confirm that in silico studies can provide insight into novel protein–ligand regulators, specifically that pyronaridine is a potential cancer drug candidate.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Molecular Dynamics SimulationNuclear ProteinsMolecular Docking SimulationBromodomain Containing ProteinsTranscription FactorsLigandsCell Cycle ProteinsNaphthyridines

Stichwörter der Autor:innen

SuperDRUG2 databasebromodomain-containing protein 4cancer diseasemolecular dockingmolecular dynamics simulations

Substanzen

Nuclear ProteinsBromodomain Containing ProteinsTranscription FactorsLigandsCell Cycle ProteinspyronaridineNaphthyridines

Autor:innen und Institutionen

  • Computational Chemistry Laboratory, Chemistry Department, Faculty of Science, Minia University, Minia 61519, Egypt.
  • School of Health Sciences, University of KwaZulu-Natal, Westville Campus, Durban 4000, South Africa.
  • Department of Pharmaceutical Chemistry, Faculty of Pharmacy, Tanta University, Tanta 31527, Egypt.
  • Department of Botany and Microbiology, College of Science, King Saud University, P.O. Box 2455, Riyadh 11451, Saudi Arabia.
  • Department of Chemistry & Biochemistry, Texas Tech University, Lubbock, TX 79409, USA.
  • Chemistry of Medicinal Plants Department, National Research Centre, 33 El-Bohouth St., Dokki, Giza 12622, Egypt.

ORCID-Profile: Mahmoud A A Ibrahim, Mahmoud M H Abdelhamid, Khlood A A Abdeljawaad, Alaa H M Abdelrahman, Gamal A H Mekhemer, Peter A Sidhom, Paul W Paré, Mohamed-Elamir F Hegazy, Tamer Shoeib

Zitieren

APA

Ibrahim, M. A. A., Abdelhamid, M. M. H., Abdeljawaad, K. A. A., Abdelrahman, A. H. M., Mekhemer, G. A. H., Sidhom, P. A., Sayed, S. R. M., Paré, P. W., Hegazy, M. F., & Shoeib, T. (2023). Pyronaridine as a Bromodomain-Containing Protein 4-N-Terminal Bromodomain (BRD4-BD1) Inhibitor: In Silico Database Mining, Molecular Docking, and Molecular Dynamics Simulation. Molecules. https://doi.org/10.3390/molecules28155713

Vancouver

Ibrahim MAA, Abdelhamid MMH, Abdeljawaad KAA, Abdelrahman AHM, Mekhemer GAH, Sidhom PA, et al. Pyronaridine as a Bromodomain-Containing Protein 4-N-Terminal Bromodomain (BRD4-BD1) Inhibitor: In Silico Database Mining, Molecular Docking, and Molecular Dynamics Simulation. Molecules. 2023. doi:10.3390/molecules28155713

BibTeX
@article{Ibrahim2023,
  author = {Ibrahim, Mahmoud A A and Abdelhamid, Mahmoud M H and Abdeljawaad, Khlood A A and Abdelrahman, Alaa H M and Mekhemer, Gamal A H and Sidhom, Peter A and Sayed, Shaban R M and Paré, Paul W and Hegazy, Mohamed-Elamir F and Shoeib, Tamer},
  title = {Pyronaridine as a Bromodomain-Containing Protein 4-N-Terminal Bromodomain (BRD4-BD1) Inhibitor: In Silico Database Mining, Molecular Docking, and Molecular Dynamics Simulation},
  journal = {Molecules},
  year = {2023},
  doi = {10.3390/molecules28155713}
}
Kostenlos starten →